No headlines found.
AVITA Medical to Announce First Quarter 2024 Financial Results
Globe Newswire (Mon, 15-Apr 5:05 PM ET)
AVITA Medical Updates Expected First Quarter 2024 Revenue
Globe Newswire (Wed, 10-Apr 5:11 PM ET)
AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement
Globe Newswire (Thu, 29-Feb 4:02 PM ET)
AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference
Globe Newswire (Thu, 29-Feb 9:00 AM ET)
AVITA Medical to Host Investor Webinar Briefing
Globe Newswire (Fri, 23-Feb 9:01 AM ET)
Globe Newswire (Thu, 22-Feb 4:01 PM ET)
AVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Results
Globe Newswire (Thu, 1-Feb 4:10 PM ET)
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Avita Medical trades on the NASDAQ stock market under the symbol RCEL.
As of April 18, 2024, RCEL stock price declined to $8.87 with 340,697 million shares trading.
RCEL has a beta of 3.95, meaning it tends to be more sensitive to market movements. RCEL has a correlation of 0.24 to the broad based SPY ETF.
RCEL has a market cap of $228.02 million. This is considered a Small Cap stock.
Last quarter Avita Medical reported $14 million in Revenue and -$.28 earnings per share. This fell short of revenue expectation by $-305,000 and exceeded earnings estimates by $.09.
In the last 3 years, RCEL stock traded as high as $22.49 and as low as $4.41.
The top ETF exchange traded funds that RCEL belongs to (by Net Assets): VTI, VXF, IWM, XBI, IWO.
RCEL has underperformed the market in the last year with a price return of -42.5% while the SPY ETF gained +22.3%. RCEL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -36.2% and -41.4%, respectively, while the SPY returned +6.1% and -3.8%, respectively.
RCEL support price is $9.01 and resistance is $9.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RCEL stock will trade within this expected range on the day.